News | Pharmaceuticals | May 24, 2022

Research Presented at AHA's QCOR Scientific Sessions Indicate Potential for Vascepa to Reduce Major Adverse CV Events

Amarin Corporation plc announced that research on the potential population health impact and cost-effectiveness of VASCEPA (icosapent ethyl), presented in two poster presentations at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions in Reston, VA, May 13-14, 2022

May 24, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost-effectiveness of VASCEPA (icosapent ethyl), presented in two poster presentations at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions in Reston, VA, May 13-14, 2022, showcased significant potential to reduce major cardiovascular (CV) events and associated costs.

The posters explored the potential for icosapent ethyl to prevent atherosclerotic cardiovascular disease-related events and associated costs among 3.6 million1 patients estimated to be eligible for treatment according to REDUCE-IT® trial criteria, and cost-effectiveness of treatment with icosapent ethyl among appropriate adult patients in the United States.

Amarin-supported abstracts to be presented at #QCOR22 included:

  • Presentation Title: The Potential Population Health Impact of Treating US Adults with Icosapent Ethyl; Abstract ID#: 244; C.G. Derington, et al, presented on behalf of all authors by Catherine G. Derington, PharmD, MS, University of Utah, Salt Lake City, UT. Publication in the American Journal of Preventive Cardiology1

    Key Conclusions: If the estimated 3.6 million REDUCE-IT eligible US adults were treated for one year with IPE, 50,000 first and 97,000 total ASCVD events could be prevented. Annually, $3.4 billion from preventing 97,000 total events (first and recurrent) could be saved, resulting in a net burden of $2.6 billion. Annual indirect ($21.6 billion) and outpatient ($23.5 billion) costs in this population are high. If a small proportion (e.g., 5%) of outpatient and indirect costs are prevented with one year of treatment, then IPE is a cost-saving therapy.

  • Presentation Title: Cost-Effectiveness of Icosapent Ethyl in Reduce-IT USA: Results from Patients Randomized In The United States; Abstract ID# 170; Z. Zhang, et al, presented on behalf of all authors by Zugui Zhang, PhD, Christiana Care Health System, Newark, DE

    Key Conclusions: The REDUCE-IT USA cost-effectiveness analysis has shown that IPE provides better outcomes with lower costs, dominant both in-trial and lifetime as well as in the majority of sensitivity analyses and subgroups, both in primary and secondary prevention. These results, with the clinical evidence of efficacy, suggest that at $4.16 per day, IE therapy should be strongly considered in patients similar to those enrolled in REDUCE-IT USA.

“The AHA has been a powerful voice in calling attention to the increasing health and economic burden on patients and our health systems from inadequately prioritizing and addressing heart disease and related risks,” said Karim Mikhail, Amarin’s president and chief executive officer. “The analyses presented at QCOR reinforce that icosapent ethyl, if prescribed and used consistently to treat eligible patients, can and should be an important tool in helping to reduce the staggering impacts and costs of cardiovascular disease in the U.S.”

For more information: www.vascepa.com

Reference:
1 Derington CG, Bress AP, Herrick JS, Fan W, Wong ND, Andrade KE, Johnson J, Philip S, Abrahamson D, Jiao L, Bhatt DL, Weintraub WS. The Potential Population Health Impact of Treating REDUCE-IT eligible US adults with Icosapent Ethyl. Am J Prev Cardiol 2022 [E-pub ahead of print]. https://doi.org/10.1016/j.ajpc.2022.100345.

Related content:

Research Shows Potential to Reduce Major Cardiovascular (CV) Events

Prescription Omega-3 Pill Did Not Affect Outcome for Non-hospitalized Adults With COVID-19

VIDEO: Icosapent Ethyl Significantly Reduces Coronary Plaque in EVAPORATE Study

Icosapent Ethyl Significantly Reduces Coronary Plaque in EVAPORATE Study

Related Content

Feature | AHA | By Dave Fornell, DAIC Editor

The following are the late-breaking science presentation sessions at the 2021 American Heart Association (AHA) 2021 ...

Home November 23, 2021
Home
News | AHA

September 20, 2021 — The American Heart Association (AHA) announced Sept. 16 it decided to convert from a planned in ...

Home September 20, 2021
Home
Feature | AHA | Dave Fornell, Editor

Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual ...

Home November 20, 2020
Home
News | AHA

July 15, 2020 – The last major cardiovascular conference to go virtual in 2020 due to the COVID-19 (SARS-Cov-2) pandemic ...

Home July 15, 2020
Home
News | AHA

November 22, 2019 — Artificial intelligence can examine electrocardiogram (ECG) test results, a common medical test, to ...

Home November 22, 2019
Home
News | AHA

November 21, 2019 — At the American Heart Association Scientific Sessions 2019, Eko, a digital health company applying ...

Home November 21, 2019
Home
News | AHA

November 21, 2019 — People who experience cardiac arrests over the weekend are less likely to survive long enough to be ...

Home November 21, 2019
Home
News | AHA

November 20, 2019 — Heart attack survivors may have an increased risk of developing cancer compared to people without ...

Home November 20, 2019
Home
News | AHA

November 20, 2019 — Ultra-processed foods, which account for more than half of an average American’s daily calories, are ...

Home November 20, 2019
Home
News | AHA

November 20, 2019 — Frequent cannabis (marijuana) use among young people was linked to an increased risk of stroke, and ...

Home November 20, 2019
Home
Subscribe Now